STENTYS -
Change in third-quarter and nine-month revenues*
* Data reviewed by the statutory auditors9 months
Quarterly - 3 months
€ thousands
9 months
2015
9 months 2014
%
change
Q3 2015
Q3 2014
%
change
Revenues
4,221.6
2,812.4
+50.1%
1,615.6
876.5
+84.3%
STENTYS recorded third quarter 2015 revenues of €1.6 million, an increase of 84% over the third quarter of 2014. Revenues comprised nearly entirely of sales from the Company's proprietary stents. The significant growth achieved was driven by the launch of the new Xposition® stent, and from sales to hospitals in the Middle East as part of the regional tender awarded to STENTYS in October 2014. MiStent SES®, currently in a controlled launch phase, contributed marginally to total revenues.
Over the first 9 months of 2015, revenues were up 50%, to €4.2 million, as compared to the first 9 months of 2014.
Gonzague Issenmann, Chief Executive Officer and co-founder of STENTYS, comments: 'Our strong third quarter performance is indicative of the growing adoption of Xposition® among interventional cardiologists, while having only been commercially available for a few months. We expect the sales momentum to continue over the coming quarters.'
- Upcoming events
Participation in the 'Salon Actionaria' investor fair on November 20 - 21, 2015, in Paris
STENTYS is developing and commercializing innovative solutions for the treatment of patients with complex coronary artery disease. STENTYS' Self-Apposing® Stents are designed to adapt to vessels with ambiguous or fluctuating diameters in order to prevent the malapposition problems associated with conventional stents. The APPOSITION clinical trials in the treatment of acute myocardial infarction showed a very low one year mortality rate and a faster arterial healing compared to conventional stents. The company's product portfolio also includes MiStent SES®, a coronary DES whose new drug delivery mechanism is designed to match vessel response, and is marketed through STENTYS' commercial
This press release contains forward-looking statements about the Company that are based on numerous assumptions regarding the Company's present and future business strategies and the environment in which it will operate in the future which may not be accurate. Such forward- looking statements involve known and unknown risks which may cause the Company's actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, risks associated with the development and commercialization of the Company's products, market acceptance of the Company's products, its ability to manage growth, the competitive environment in relation to its business area and markets, its ability to enforce and protect its patents and proprietary rights, uncertainties related to the U.S. FDA approval process, slower than expected rates of patient recruitment for clinical trials, the outcome of clinical trials, and other factors, including those described in the Section 4 'Risk Factors' of the Company's 2014 Registration Document (document de référence) filed with the French Autorité des Marchés Financiers on July 29, 2015 under number D.15-0807 as such section may be updated from time to time.
Page 1 of 2
STENTYS Stanislas Piot CFO Tel.: +33 (0)1 44 53 99 42 stan.p@stentys.com | NewCap Investor Relations / Strategic Communications Dusan Oresansky Tel.: +33 (0)1 44 71 94 93 stentys@newcap.eu | LifeSci Advisors LLC Andrew McDonald Tel: +1.646.597.6987 andrew@lifesciadvisors.com |
STENTYS is listed on Comp. C of the Euronext Paris market ISIN: FR0010949404 - Ticker: STNT | ||
Page 2 of 2
|
distributed by
|
